OncoMatch/Clinical Trials/NCT06863402
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Is NCT06863402 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Nemtabrutinib for richter syndrome.
Treatment: Nemtabrutinib · Pembrolizumab — This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as Richter transformation at abnormal levels. This may help keep cancer cells from growing and spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving nemtabrutinib in combination with pembrolizumab may kill more cancer cells in patients with RT-DLBCL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX40, CD137)
Lab requirements
Blood counts
ANC ≥ 500 cells/µL (without G-CSF dose within the last 7 days prior to initiation of study treatment); Platelets: ≥ 25,000/µL (not requiring transfusion within the last 3 days prior to initiation of study treatment); Hemoglobin: ≥ 7gm/dL (transfusion support allowed)
Kidney function
Creatinine clearance (CrCl): ≥ 30 mL/min (per Cockroft-Gault equation)
Liver function
Total bilirubin: ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 x ULN. AST/ALT: ≤ 2.5 x ULN (≤ 5 x ULN for participants with liver metastases)
Cardiac function
Corrected QT interval (QTc) prolongation (QTcF > 450 msecs) or other significant ECG abnormalities including second degree AV block type II, third degree AV block, or bradycardia (ventricular rate less than 50 beats/min) are excluded
ANC ≥ 500 cells/µL... Platelets: ≥ 25,000/µL... Hemoglobin: ≥ 7gm/dL... Total bilirubin: ≤ 1.5 x ULN OR direct bilirubin ≤ ULN... AST/ALT: ≤ 2.5 x ULN (≤ 5 x ULN for participants with liver metastases)... Creatinine clearance (CrCl): ≥ 30 mL/min... Corrected QT interval (QTc) prolongation (QTcF > 450 msecs) or other significant ECG abnormalities including second degree AV block type II, third degree AV block, or bradycardia (ventricular rate less than 50 beats/min) are excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Roswell Park Cancer Institute · Buffalo, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06863402 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify